Weekly Investment Analysts’ Ratings Changes for Zoetis (ZTS)

A number of firms have modified their ratings and price targets on shares of Zoetis (NYSE: ZTS) recently:

• 5/22/2026 – Zoetis had its price target lowered by Stifel Nicolaus from $105.00 to $95.00. They now have a “hold” rating on the stock.
• 5/18/2026 – Zoetis had its price target lowered by Citigroup Inc. from $145.00 to $112.00. They now have a “buy” rating on the stock.
• 5/15/2026 – Zoetis had its “overweight” rating reaffirmed by Morgan Stanley. They now have a $115.00 price target on the stock.
• 5/8/2026 – Zoetis had its price target lowered by UBS Group AG from $130.00 to $99.00. They now have a “neutral” rating on the stock.
• 5/8/2026 – Zoetis was given a new $105.00 price target by Stifel Nicolaus.
• 5/8/2026 – Zoetis had its price target lowered by JPMorgan Chase & Co. from $190.00 to $130.00. They now have an “overweight” rating on the stock.
• 5/2/2026 – Zoetis was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/28/2026 – Zoetis had its price target lowered by UBS Group AG from $136.00 to $130.00. They now have a “neutral” rating on the stock.
• 4/15/2026 – Zoetis is now covered by Citigroup Inc.. They set a “buy” rating and a $145.00 price target on the stock.
• 4/15/2026 – Zoetis is now covered by Citigroup Inc.. They set a “buy” rating and a $145.00 price target on the stock.
• 3/27/2026 – Zoetis was downgraded by Weiss Ratings from “hold (c-)” to “sell (d+)”.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 2.6%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is presently 35.16%.

Insider Activity

In other news, Director Michael B. Mccallister acquired 3,000 shares of the firm’s stock in a transaction dated Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the completion of the acquisition, the director owned 24,524 shares of the company’s stock, valued at $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Paul Bisaro purchased 2,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director owned 27,862 shares of the company’s stock, valued at approximately $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last ninety days, insiders bought 11,650 shares of company stock valued at $886,384. 0.22% of the stock is currently owned by company insiders.

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.